Zn‐Based Multi‐Active Framework Nanoparticles TSA‐CAN‐Zn Inhibit Skin Glycation via Dual Blockade of HMGB1/RAGE and AGEs/RAGE Pathways
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202500664 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Cheng Yao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cheermore Cosmetic Dermatology Laboratory, Shanghai, China. Hauptthemen laut MEDLINE: Glycation End Products, Advanced, HMGB1 Protein, Skin, Receptor for Advanced Glycation End Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Technology Innovation Project of Nankai University & Zhiben Synthetic Biology Joint Laboratory.
Abstract (Originalsprache)
Receptor for advanced glycation end products (RAGE) plays an important role in skin glycation damage. High‐mobility group 1B protein (HMGB1) and advanced glycation end products (AGEs) are key RAGE ligands. Simultaneous inhibition of HMGB1/RAGE and AGEs/RAGE pathways maybe an effective strategy to alleviate glycation induced skin damage. In this work, Theasinensin A (TSA) is identified as the active molecule inhibiting HMGB1‐RAGE interaction through molecular docking. To simultaneously suppress HMGB1/RAGE and AGEs/RAGE pathways, Zn‐based multi‐active framework nanoparticles TSA‐CAN‐Zn are designed, which contain TSA and the active molecule L‐carnosine (CAN) that inhibits AGEs production. In vitro studies demonstrated that TSA‐CAN‐Zn have radical scavenging activity and AGEs formation inhibition activity. TSA‐CAN‐Zn can not only inhibit ROS accumulation, cell apoptosis, and inflammatory factors production induced by glycation in HaCaT cells but also enhanced the lysosomal degradation of AGEs. TSA‐CAN‐Zn also mitigated the damage caused by glycation in mouse skin glycation model. Single‐cell RNA sequencing results revealed the impact of TSA‐CAN‐Zn on different cell types of skin tissue, especially the basal cells of the epidermal layer and inflammation‐related macrophages. And pathway analysis revealed that TSA‐CAN‐Zn mainly influences the downstream pathways of RAGE. Collectively, TSA‐CAN‐Zn is a promising therapeutic candidate for ameliorating glycation‐induced skin damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cheermore Cosmetic Dermatology Laboratory, Shanghai, China.
- Shanghai Cheermore Aesthetic Clinic, Shanghai, China.
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
- Medical plastic and cosmetic center, Tianjin Branch of National Clinical Research Center for Ocular Disease, Tianjin Medical University Eye Hospital, Tianjin, China.
ORCID-Profile: Huijuan Liu
Förderung
- Technology Innovation Project of Nankai University & Zhiben Synthetic Biology Joint Laboratory
Zitieren
APA
Yao, C., Wang, H., Han, J., Yang, K., Lin, T., Jin, J., Zhu, C., & Liu, H. (2025). Zn‐Based Multi‐Active Framework Nanoparticles TSA‐CAN‐Zn Inhibit Skin Glycation via Dual Blockade of HMGB1/RAGE and AGEs/RAGE Pathways. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500664
Vancouver
Yao C, Wang H, Han J, Yang K, Lin T, Jin J, et al. Zn‐Based Multi‐Active Framework Nanoparticles TSA‐CAN‐Zn Inhibit Skin Glycation via Dual Blockade of HMGB1/RAGE and AGEs/RAGE Pathways. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500664
BibTeX
@article{Yao2025,
author = {Yao, Cheng and Wang, Heqi and Han, Jingxia and Yang, Kai and Lin, Tingting and Jin, Jing and Zhu, Caibin and Liu, Huijuan},
title = {Zn‐Based Multi‐Active Framework Nanoparticles TSA‐CAN‐Zn Inhibit Skin Glycation via Dual Blockade of HMGB1/RAGE and AGEs/RAGE Pathways},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202500664}
}
EUVIMED